



## Clinical trial results:

### Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia

#### Summary

EudraCT number	2007-007587-21
Trial protocol	DE AT DK CZ
Global end of trial date	01 January 2018

#### Results information

Result version number	v1 (current)
This version publication date	21 August 2020
First version publication date	21 August 2020

#### Trial information

##### Trial identification

Sponsor protocol code	CLL10
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00769522
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	German CLL Study Group, University Hospital Cologne
Sponsor organisation address	Gleuelerstr. 176-178, Cologne, Germany, 50935
Public contact	Information Desk, German CLL Study Group, +49 22147888198, cll-studie@uk-koeln.de
Scientific contact	Information Desk, German CLL Study Group, +49 22147888198, cll-studie@uk-koeln.de

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 March 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 December 2017
Global end of trial reached?	Yes
Global end of trial date	01 January 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective is to demonstrate that BR has a non-inferior therapeutic efficacy compared with FCR, but a better safety profile causing less myelosuppression, infections and secondary neoplasias.

Protection of trial subjects:

For a prevention of an anaphylactic reaction and a cytokine release Syndrome patients should be pretreated with antihistamines, Paracetamol/Acetaminophen and Prednisolon.

In case of a leukocytopenia CTC grade 3 or 4 with a Duration of >7 days, prophylaxis of pneumocystis carinii-pneumonia is recommended. Other routine measures such as antibiotic, antimycotic or viostatic prophylaxis as well as the use of growth factors should be given if clinically indicated.

Background therapy:

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) is the Standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia and Background therapy in the CLL10-trial.

Following the results of a Phase 2 study by the MD Anderson Cancer Center and a Phase 3 Study by the German CLL-Study Group, the CLL8 study, FCR has become the Standard front-line therapy for physically fit patients with chronic lymphocytic leukemia. However this Regimen is associated with substantial toxic effects, most importantly severe haematotoxicity in 56% of patients and severe infections in 25% of patients during treatment. A Long-term follow-up of patients treated with FCR showed prolonged neutropenia in 17-35% and an elevated risk of secondary neoplasia.

Evidence for comparator:

Chemoimmunotherapy with bendamustine and rituximab (BR) is the comparator. The combination of the alkylating Agent bendamustine and rituximab has shown promising results in a Phase 2 study in front-line therapy of chronic lymphocytic leukaemia with Overall responses in 103 of 117 patients and complete responses in 27 of 117 patients. Event-free survival of 34 months and low incidence of severe neutropenia (20%) and infections (8%) led to the hypothesis that the treatment with BR might be similarly effective but less toxic compared with the Standard treatment FCR.

Actual start date of recruitment	02 October 2008
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	6 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 10
Country: Number of subjects enrolled	Czech Republic: 4
Country: Number of subjects enrolled	Denmark: 24
Country: Number of subjects enrolled	Germany: 487
Country: Number of subjects enrolled	Switzerland: 36

Worldwide total number of subjects	561
EEA total number of subjects	525

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	353
From 65 to 84 years	208
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

564 patients were enrolled between 10/2008 and 04/2012. The patients were randomly assigned to FCR (284) and BR (280) .

561 patients were allocated to treatment because 3 patients dropped off during the randomisation process. 282 patients were allocated to FCR and 279 patients were allocated to BR (baseline values).

### Pre-assignment

Screening details:

688 treatment-naïve patients diagnosed with CLL were registered for central screening . The central screening was performed by the GCLLSG central study office in Cologne, Germany and included immunophenotyping, FISH, evaluation of the comorbidity and renal function. 127 patients were not eligible for participation.

### Pre-assignment period milestones

Number of subjects started	688 <sup>[1]</sup>
Number of subjects completed	561

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Protocol deviation: 127
----------------------------	-------------------------

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: All patients who meet the eligibility criteria for study entry can be enrolled into the trial. To verify the eligibility of patients, a patient screening by a medical review of the pretherapeutic staging as well as a central immunophenotyping for confirmation of the diagnosis and FISH analysis to exclude patients with a 17p deletion or mutation will be performed before randomization.

688 patients started pre-assignment period. 127 patients were assessed as Screening failures. 561 completed.

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Fludarabine/Cyclophosphamide/Rituximab

Arm description:

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab.

Arm type	Standard
Investigational medicinal product name	Fludarabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Cycle 1-6 on days 1-3: 25mg/m<sup>2</sup>

Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	Cytoxan
Pharmaceutical forms	Powder for solution for infusion

Routes of administration	Intravenous use
Dosage and administration details: 250 mg/m <sup>2</sup> cycle 1-6 on days 1, 2, 3.	
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	Rituxan, Truxima
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: Cycle 1: 375 mg/ m <sup>2</sup> i.v. on day 0 Cycles 2-6: 500 mg/ m <sup>2</sup> i.v. on day 1 (before FC)	

<b>Arm title</b>	Bendamustine/Rituximab
Arm description: Chemoimmunotherapy with bendamustine and rituximab	
Arm type	Active comparator
Investigational medicinal product name	Bendamustine
Investigational medicinal product code	
Other name	Ribomustin, Treanda
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use
Dosage and administration details: 90 mg/m <sup>2</sup> course 1-6, days 1 and 2	
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	Rituxan, Truxima
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: Cycle1: 375mg/m <sup>2</sup> i.v. on day 0 cycles 2-6: 500 mg/m <sup>2</sup> i.v. on day 1 (before FC)	

<b>Number of subjects in period 1</b>	Fludarabine/Cyclophosphamide/Rituximab	Bendamustine/Rituximab
Started	282	279
treatment allocation	282	279
treatment	282	279
follow-up	282	279
Completed	199	224
Not completed	83	55
Adverse event, serious fatal	3	1
withdrawal of consent before start of treatment	3	1
Adverse event, non-fatal	65	38
various reasons	10	14
Lack of efficacy	2	1



## Baseline characteristics

### Reporting groups

Reporting group title	Fludarabine/Cyclophosphamide/Rituximab
Reporting group description:	Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab.
Reporting group title	Bendamustine/Rituximab
Reporting group description:	Chemoimmunotherapy with bendamustine and rituximab

Reporting group values	Fludarabine/Cyclophosphamide/Rituximab	Bendamustine/Rituximab	Total
Number of subjects	282	279	561
Age categorical			
Median Age 60.5 years for FCR and 62.0 years for BR.			
Units: Subjects			
Adults (18-64 years)	187	166	353
65 years and over	95	113	208
Age continuous			
Units: years			
median	60.5	62	
inter-quartile range (Q1-Q3)	55 to 67	54 to 69	-
Gender categorical			
Units: Subjects			
Female	81	72	153
Male	201	207	408

### Subject analysis sets

Subject analysis set title	CLL10 Clinical Study Report
Subject analysis set type	Intention-to-treat

Subject analysis set description:

The intent-to-treat population (ITT) included all randomized subjects. 561 Patients (282 patients in the FCR arm and 279 patients in the BR arm) were assessed for progression free survival PFS (primary endpoint). PFS was measured from the date of randomization to the date of first documented disease progression (as defined by the IWCLL 2008 response criteria) or death by any cause, whichever occurred first. Following secondary endpoints were assessed: duration of Remission, event free survival (EFS), overall survival (OS), MRD, complete response rates and partial remission rates, response rates and survival times in biological subgroups, rates of toxicities and quality of life.

Reporting group values	CLL10 Clinical Study Report		
Number of subjects	561		
Age categorical			
Median Age 60.5 years for FCR and 62.0 years for BR.			
Units: Subjects			
Adults (18-64 years)	353		
65 years and over	208		

Age continuous			
Units: years			
median	61		
inter-quartile range (Q1-Q3)	54.5 to 68.0		
Gender categorical			
Units: Subjects			
Female	153		
Male	408		

---

## End points

### End points reporting groups

Reporting group title	Fludarabine/Cyclophosphamide/Rituximab
-----------------------	--

Reporting group description:

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab.

Reporting group title	Bendamustine/Rituximab
-----------------------	------------------------

Reporting group description:

Chemoimmunotherapy with bendamustine and rituximab

Subject analysis set title	CLL10 Clinical Study Report
----------------------------	-----------------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

The intent-to-treat population (ITT) included all randomized subjects. 561 Patients (282 patients in the FCR arm and 279 patients in the BR arm) were assessed for progression free survival PFS (primary endpoint). PFS was measured from the date of randomization to the date of first documented disease progression (as defined by the IWCLL 2008 response criteria) or death by any cause, whichever occurred first. Following secondary endpoints were assessed:

duration of Remission, event free survival (EFS), overall survival (OS), MRD, complete response rates and partial remission rates, response rates and survival times in biological subgroups, rates of toxicities and quality of life.

### Primary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
-----------------	---------------------------------

End point description:

Progression free survival will be calculated as the time between date of randomization and date of progression or death of any cause.

End point type	Primary
----------------	---------

End point timeframe:

The progression free survival (PFS) rate after 24 months

End point values	Fludarabine/Cyclophosphamide/Rituximab	Bendamustine/Rituximab	CLL10 Clinical Study Report	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	282	279	561	
Units: PFS rates at 24 months				
number (not applicable)	84.3	77.8	81.0	

### Statistical analyses

Statistical analysis title	Statistical plan for primary endpoint
----------------------------	---------------------------------------

Statistical analysis description:

Progression-free survival (PFS) is defined as the time from randomization to disease progression or death from any cause. These will be counted as events for PFS. Patients who have neither progressed nor died will be censored.

A Cox proportional hazard model will be applied on progression-free survival time including the variables for study medication and the stratification parameters as covariates. If the upper limit of the 90.4%-confidence interval of the hazard-ratio of BR compared to FCR is

Comparison groups	Fludarabine/Cyclophosphamide/Rituximab v
-------------------	--

Bendamustine/Rituximab	
Number of subjects included in analysis	561
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
P-value	< 0.001 <sup>[2]</sup>
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.643
Confidence interval	
level	90.4 %
sides	1-sided
upper limit	2.064

Notes:

[1] - The significance level of the study is 5% (one-sided, with one interim analysis and one final analysis using the method of O'Brien and Fleming to allocate the global 5% significance level to the 2 analyses), the significance level of the final analysis is accordingly 4.8%. The power is 80%. The CLL 10 protocol is a non-inferiority trial. The expected PFS 2 years after start of FCR therapy is 75% which translates to an exponential parameter of 0.1438.

[2] - A p value < 0.001 and an upper limit of the 90.4% confidence interval is greater than 1.388. Thus, the null hypothesis for the corresponding non-inferiority hypothesis cannot be rejected according to the protocol.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Chemoimmunotherapy BR
-----------------------	-----------------------

Reporting group description: -

Reporting group title	Chemoimmunotherapy FCR
-----------------------	------------------------

Reporting group description: -

<b>Serious adverse events</b>	Chemoimmunotherapy BR	Chemoimmunotherapy FCR	
Total subjects affected by serious adverse events			
subjects affected / exposed	135 / 278 (48.56%)	155 / 279 (55.56%)	
number of deaths (all causes)	78	69	
number of deaths resulting from adverse events	14	20	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia	Additional description: Acute myeloid leukaemia		
subjects affected / exposed	1 / 278 (0.36%)	4 / 279 (1.43%)	
occurrences causally related to treatment / all	0 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	3 / 3	
Adenocarcinoma	Additional description: Adenocarcinoma		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	1 / 278 (0.36%)	4 / 279 (1.43%)	
occurrences causally related to treatment / all	1 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer	Additional description: Bladder cancer		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
Additional description: Bladder neoplasm			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
Additional description: Breast cancer			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			
Additional description: Bronchial carcinoma			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Breast cancer female			
Additional description: Breast cancer female			
subjects affected / exposed	1 / 278 (0.36%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell sarcoma of the kidney			
Additional description: Clear cell sarcoma of the kidney			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			
Additional description: Colon cancer metastatic			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
Additional description: Colorectal cancer			
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma			
Additional description: Glioblastoma			

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Malignant melanoma</b>	Additional description: Malignant melanoma		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Malignant neoplasm of unknown primary site</b>	Additional description: Malignant neoplasm of unknown primary site		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Myelodysplastic syndrome</b>	Additional description: Myelodysplastic syndrome		
subjects affected / exposed	1 / 278 (0.36%)	4 / 279 (1.43%)	
occurrences causally related to treatment / all	0 / 1	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Metastatic neoplasm</b>	Additional description: Metastatic neoplasm		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Oesophageal adenocarcinoma</b>	Additional description: Oesophageal adenocarcinoma		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Prostate cancer</b>	Additional description: Prostate cancer		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Rectal cancer</b>	Additional description: Rectal cancer		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Refractory anaemia with an excess of blasts</b>	Additional description: Refractory anaemia with an excess of blasts		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
Additional description: Skin cancer			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of skin			
Additional description: Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
Additional description: Thyroid cancer			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
Additional description: Transitional cell carcinoma			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
Additional description: Aortic aneurysm			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
Additional description: Deep vein thrombosis			
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
Additional description: Hypertension			
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
Additional description: Intermittent claudication			

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis	Additional description: Peripheral artery stenosis		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures	Additional description: Hernia repair		
Hernia repair	Additional description: Hernia repair		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty	Additional description: Hip arthroplasty		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip surgery	Additional description: Hip surgery		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc operation	Additional description: Intervertebral disc operation		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation	Additional description: Knee operation		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung lobectomy	Additional description: Lung lobectomy		

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus operation			
Additional description: Meniscus operation			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagectomy			
Additional description: Oesophagectomy			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Osteotomy			
Additional description: Osteotomy			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile prosthesis insertion			
Additional description: Penile prosthesis insertion			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatectomy			
Additional description: Prostatectomy			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal operation			
Additional description: Spinal operation			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal laminectomy			
Additional description: Spinal laminectomy			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal decompression			
Additional description: Spinal decompression			

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroidectomy	Additional description: Thyroidectomy		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain	Additional description: Chest pain		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death	Additional description: Death		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 2	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	17 / 278 (6.12%)	15 / 279 (5.38%)	
occurrences causally related to treatment / all	14 / 17	17 / 19	
deaths causally related to treatment / all	0 / 0	1 / 1	
Immune system disorders			
Anaphylactic reaction	Additional description: Anaphylactic reaction		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock	Additional description: Anaphylactic shock		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed	4 / 278 (1.44%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	4 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Drug hypersensitivity	Additional description: Drug hypersensitivity	
subjects affected / exposed	3 / 278 (1.08%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypersensitivity	Additional description: Hypersensitivity	
subjects affected / exposed	7 / 278 (2.52%)	2 / 279 (0.72%)
occurrences causally related to treatment / all	7 / 7	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Serum sickness	Additional description: Serum sickness	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Reproductive system and breast disorders		
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Calculus prostatic	Additional description: Calculus prostatic	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Prostatitis	Additional description: Prostatitis	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders		
Aspiration	Additional description: Aspiration	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Asthma	Additional description: Asthma	

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Bronchial haemorrhage	Additional description: Bronchial haemorrhage		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
-----			
Chylothorax	Additional description: Chylothorax		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Hiccups	Additional description: Hiccups		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Lung infiltration	Additional description: Lung infiltration		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed	1 / 278 (0.36%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pneumonitis	Additional description: Pneumonitis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pneumothorax	Additional description: Pneumothorax		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pulmonary embolism	Additional description: Pulmonary embolism		
subjects affected / exposed	3 / 278 (1.08%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
-----			
Pulmonary sarcoidosis	Additional description: Pulmonary sarcoidosis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Respiratory disorder	Additional description: Respiratory disorder		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Psychiatric disorders			
Alcoholism	Additional description: Alcoholism		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Acute psychosis	Additional description: Acute psychosis		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Investigations			
Arthroscopy	Additional description: Arthroscopy		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Biopsy adrenal gland	Additional description: Biopsy adrenal gland		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Blood sodium decreased	Additional description: Blood sodium decreased		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigation	Additional description: Investigation		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count	Additional description: Neutrophil count		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Allergic transfusion reaction	Additional description: Allergic transfusion reaction		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture	Additional description: Ankle fracture		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial injury	Additional description: Arterial injury		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture	Additional description: Cervical vertebral fracture		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall	Additional description: Fall		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
Additional description: Femoral neck fracture			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
Additional description: Foot fracture			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
Additional description: Infusion related reaction			
subjects affected / exposed	3 / 278 (1.08%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	4 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
Additional description: Post procedural haematuria			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
Additional description: Road traffic accident			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
Additional description: Tendon rupture			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transfusion reaction			
Additional description: Transfusion reaction			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
Additional description: Acute coronary syndrome			

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
Additional description: Acute myocardial infarction			
subjects affected / exposed	3 / 278 (1.08%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Arrhythmia			
Additional description: Arrhythmia			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
Additional description: Atrial fibrillation			
subjects affected / exposed	4 / 278 (1.44%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
Additional description: Atrial flutter			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
Additional description: Atrial tachycardia			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
Additional description: Bradycardia			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
Additional description: Cardiac failure			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery dilatation			
Additional description: Coronary artery dilatation			

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction	Additional description: Myocardial infarction		
subjects affected / exposed	3 / 278 (1.08%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial ischaemia	Additional description: Myocardial ischaemia		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion	Additional description: Pericardial effusion		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia	Additional description: Tachyarrhythmia		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebellar ischaemia	Additional description: Cerebellar ischaemia		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia	Additional description: Cerebral ischaemia		

subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic hyperosmolar coma	Additional description: Diabetic hyperosmolar coma		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness	Additional description: Dizziness		
subjects affected / exposed	0 / 278 (0.00%)	3 / 279 (1.08%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Horner's syndrome	Additional description: Horner's syndrome		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukoencephalopathy	Additional description: Leukoencephalopathy		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia	Additional description: Paraesthesia		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope	Additional description: Syncope		
subjects affected / exposed	3 / 278 (1.08%)	3 / 279 (1.08%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack	Additional description: Transient ischaemic attack		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		

subjects affected / exposed	0 / 278 (0.00%)	6 / 279 (2.15%)	
occurrences causally related to treatment / all	0 / 0	6 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	13 / 278 (4.68%)	18 / 279 (6.45%)	
occurrences causally related to treatment / all	11 / 13	18 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Febrile bone marrow aplasia	Additional description: Febrile bone marrow aplasia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Haemolysis	Additional description: Haemolysis		
subjects affected / exposed	1 / 278 (0.36%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Haemolytic anaemia	Additional description: Haemolytic anaemia		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Leukopenia	Additional description: Leukopenia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	1 / 278 (0.36%)	4 / 279 (1.43%)	
occurrences causally related to treatment / all	1 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Platelet disorder	Additional description: Platelet disorder		

subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders	Additional description: Vertigo positional		
Vertigo positional	Additional description: Vertigo positional		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders	Additional description: Retinal detachment		
Retinal detachment	Additional description: Retinal detachment		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders	Additional description: Abdominal pain		
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute abdomen	Additional description: Acute abdomen		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphthous stomatitis	Additional description: Aphthous stomatitis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation	Additional description: Constipation		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Diarrhoea	Additional description: Diarrhoea	
subjects affected / exposed	0 / 278 (0.00%)	3 / 279 (1.08%)
occurrences causally related to treatment / all	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Diverticulum	Additional description: Diverticulum	
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Gastritis erosive	Additional description: Gastritis erosive	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroesophageal reflux disease	Additional description: Gastroesophageal reflux disease	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Inguinal hernia	Additional description: Inguinal hernia	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Large intestine perforation	Additional description: Large intestine perforation	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Nausea	Additional description: Nausea	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Neutropenic colitis	Additional description: Neutropenic colitis	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1
Pancreatitis	Additional description: Pancreatitis	

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting	Additional description: Vomiting		
subjects affected / exposed	2 / 278 (0.72%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	2 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders	Additional description: Cholelithiasis		
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiolitis	Additional description: Cholangiolitis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis toxic	Additional description: Hepatitis toxic		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity	Additional description: Hepatotoxicity		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders	Additional description: Dermatitis allergic		
Dermatitis allergic	Additional description: Dermatitis allergic		
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema	Additional description: Eczema		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema	Additional description: Erythema		

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukoplakia	Additional description: Leukoplakia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash	Additional description: Rash		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash generalised	Additional description: Rash generalised		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic epidermal necrolysis	Additional description: Toxic epidermal necrolysis		
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders	Additional description: Bladder malposition acquired		
Bladder malposition acquired	Additional description: Bladder malposition acquired		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus ureteric	Additional description: Calculus ureteric		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis	Additional description: Nephrolithiasis		

subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Arthritis</b>	Additional description: Arthritis		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Arthrofibrosis</b>	Additional description: Arthrofibrosis		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Back pain</b>	Additional description: Back pain		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Osteoarthritis</b>	Additional description: Osteoarthritis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Abscess of salivary gland</b>	Additional description: Abscess of salivary gland		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anal abscess</b>	Additional description: Anal abscess		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bacterial sepsis</b>	Additional description: Bacterial sepsis		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bacterial infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bacterial infection	
	0 / 278 (0.00%)	1 / 279 (0.36%)
	0 / 0	0 / 1
Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bronchitis	
	3 / 278 (1.08%)	6 / 279 (2.15%)
	0 / 4	3 / 7
Bronchopneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bronchopneumonia	
	3 / 278 (1.08%)	3 / 279 (1.08%)
	1 / 3	1 / 4
Bronchopulmonary aspergillosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bronchopulmonary aspergillosis	
	0 / 278 (0.00%)	1 / 279 (0.36%)
	0 / 0	1 / 1
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cellulitis	
	1 / 278 (0.36%)	0 / 279 (0.00%)
	1 / 1	0 / 0
Chronic sinusitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Chronic sinusitis	
	0 / 278 (0.00%)	1 / 279 (0.36%)
	0 / 0	0 / 1
Clostridium difficile sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Clostridium difficile sepsis	
	0 / 278 (0.00%)	1 / 279 (0.36%)
	0 / 0	1 / 1
Cystitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cystitis	
	0 / 278 (0.00%)	2 / 279 (0.72%)
	0 / 0	2 / 2
Diverticulitis	Additional description: Diverticulitis	

subjects affected / exposed	2 / 278 (0.72%)	3 / 279 (1.08%)	
occurrences causally related to treatment / all	2 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
Additional description: Erysipelas			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
Additional description: Escherichia urinary tract infection			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
Additional description: Febrile infection			
subjects affected / exposed	3 / 278 (1.08%)	6 / 279 (2.15%)	
occurrences causally related to treatment / all	3 / 3	4 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
Additional description: Gastroenteritis			
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis clostridial			
Additional description: Gastroenteritis clostridial			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
Additional description: Gastrointestinal infection			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
Additional description: Gastroenteritis norovirus			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genital herpes			
Additional description: Genital herpes			

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
H1N1 influenza	Additional description: H1N1 influenza		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Hepatitis B	Additional description: Hepatitis B		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
-----			
Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	2 / 278 (0.72%)	9 / 279 (3.23%)	
occurrences causally related to treatment / all	0 / 2	3 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Herpes zoster oticus	Additional description: Herpes zoster oticus		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Influenza	Additional description: Influenza		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Infection	Additional description: Infection		
subjects affected / exposed	3 / 278 (1.08%)	4 / 279 (1.43%)	
occurrences causally related to treatment / all	5 / 6	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Lung infection	Additional description: Lung infection		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
-----			
Neutropenic infection	Additional description: Neutropenic infection		

subjects affected / exposed	4 / 278 (1.44%)	3 / 279 (1.08%)	
occurrences causally related to treatment / all	4 / 4	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
Additional description: Neutropenic sepsis			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
Additional description: Oesophageal candidiasis			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
Additional description: Pharyngitis			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural infection			
Additional description: Pleural infection			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
Additional description: Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 278 (0.36%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
Additional description: Pneumonia bacterial			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
Additional description: Pneumonia			
subjects affected / exposed	21 / 278 (7.55%)	25 / 279 (8.96%)	
occurrences causally related to treatment / all	13 / 22	16 / 31	
deaths causally related to treatment / all	2 / 2	1 / 2	
Pneumonia haemophilus			
Additional description: Pneumonia haemophilus			

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal	Additional description: Pneumonia mycoplasmal		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal	Additional description: Pneumonia pneumococcal		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral	Additional description: Pneumonia viral		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural sepsis	Additional description: Post procedural sepsis		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Progressive multifocal leukoencephalopathy	Additional description: Progressive multifocal leukoencephalopathy		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pulmonary sepsis	Additional description: Pulmonary sepsis		
subjects affected / exposed	1 / 278 (0.36%)	3 / 279 (1.08%)	
occurrences causally related to treatment / all	1 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	1 / 2	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection	Additional description: Rhinovirus infection		

subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
Additional description: Scrotal abscess			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
Additional description: Sepsis			
subjects affected / exposed	3 / 278 (1.08%)	5 / 279 (1.79%)	
occurrences causally related to treatment / all	1 / 3	3 / 5	
deaths causally related to treatment / all	1 / 2	2 / 2	
Sinobronchitis			
Additional description: Sinobronchitis			
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
Additional description: Sinusitis			
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
Additional description: Soft tissue infection			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
Additional description: Tonsillitis			
subjects affected / exposed	2 / 278 (0.72%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
Additional description: Urinary tract infection			
subjects affected / exposed	2 / 278 (0.72%)	7 / 279 (2.51%)	
occurrences causally related to treatment / all	2 / 2	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
Additional description: Upper respiratory tract infection			

subjects affected / exposed	3 / 278 (1.08%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
Additional description: Urosepsis			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemia			
Additional description: Hyperglycaemia			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
Additional description: Lactic acidosis			
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Chemoimmunotherapy BR	Chemoimmunotherapy FCR	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	248 / 278 (89.21%)	271 / 279 (97.13%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
Additional description: Basal cell carcinoma			
subjects affected / exposed	2 / 278 (0.72%)	2 / 279 (0.72%)	
occurrences (all)	2	3	
Breast cancer			
Additional description: Breast cancer			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Colon adenoma			
Additional description: Colon adenoma			
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Histiocytosis			
Additional description: Histiocytosis			

subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Oesophageal adenocarcinoma	Additional description: Oesophageal adenocarcinoma		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2	
Seborrhoeic keratosis	Additional description: Seborrhoeic keratosis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Skin cancer	Additional description: Skin cancer		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Skin papilloma	Additional description: Skin papilloma		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	1 / 279 (0.36%) 1	
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Thyroid cancer	Additional description: Thyroid cancer		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Vascular disorders			
Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Haemorrhage	Additional description: Haemorrhage		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Hot flush	Additional description: Hot flush		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Hypertension	Additional description: Hypertension		
subjects affected / exposed occurrences (all)	4 / 278 (1.44%) 4	2 / 279 (0.72%) 3	
Hypotension	Additional description: Hypotension		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	0 / 279 (0.00%) 0	

Labile blood pressure subjects affected / exposed occurrences (all)	Additional description: Labile blood pressure	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Peripheral ischaemia subjects affected / exposed occurrences (all)	Additional description: Peripheral ischaemia	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Phlebitis subjects affected / exposed occurrences (all)	Additional description: Phlebitis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Post thrombotic syndrome subjects affected / exposed occurrences (all)	Additional description: Post thrombotic syndrome	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 3
Thrombosis subjects affected / exposed occurrences (all)	Additional description: Thrombosis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Thrombophlebitis subjects affected / exposed occurrences (all)	Additional description: Thrombophlebitis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Varicose vein subjects affected / exposed occurrences (all)	Additional description: Varicose vein	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Venous thrombosis limb subjects affected / exposed occurrences (all)	Additional description: Venous thrombosis limb	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Surgical and medical procedures Catheter management subjects affected / exposed occurrences (all)	Additional description: Catheter management	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Cervical conisation subjects affected / exposed occurrences (all)	Additional description: Cervical conisation	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Haemorrhoid operation subjects affected / exposed occurrences (all)	Additional description: Haemorrhoid operation	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Hysterectomy	Additional description: Hysterectomy	

subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Immunoglobulin therapy	Additional description: Immunoglobulin therapy		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Papilloma excision	Additional description: Papilloma excision		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Shoulder operation	Additional description: Shoulder operation		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Skin neoplasm excision	Additional description: Skin neoplasm excision		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
General disorders and administration site conditions			
Asthenia	Additional description: Asthenia		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Chest pain	Additional description: Chest pain		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Chills	Additional description: Chills		
subjects affected / exposed occurrences (all)	4 / 278 (1.44%) 4	1 / 279 (0.36%) 1	
Fatigue	Additional description: Fatigue		
subjects affected / exposed occurrences (all)	6 / 278 (2.16%) 8	8 / 279 (2.87%) 16	
Generalised oedema	Additional description: Generalised oedema		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Inflammation	Additional description: Inflammation		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Influenza like illness	Additional description: Influenza like illness		

subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	3 / 279 (1.08%) 5	
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 3	2 / 279 (0.72%) 2	
Oedema	Additional description: Oedema		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	0 / 279 (0.00%) 0	
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed occurrences (all)	38 / 278 (13.67%) 45	42 / 279 (15.05%) 57	
Ulcer	Additional description: Ulcer		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Immune system disorders			
Anaphylactic reaction	Additional description: Anaphylactic reaction		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 3	1 / 279 (0.36%) 1	
Drug hypersensitivity	Additional description: Drug hypersensitivity		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed occurrences (all)	17 / 278 (6.12%) 19	10 / 279 (3.58%) 10	
Hypogammaglobulinaemia	Additional description: Hypogammaglobulinaemia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 4	0 / 279 (0.00%) 0	

Type IV hypersensitivity reaction subjects affected / exposed occurrences (all)	Additional description: Type IV hypersensitivity reaction		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Reproductive system and breast disorders			
Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	Additional description: Benign prostatic hyperplasia		
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Erectile dysfunction subjects affected / exposed occurrences (all)	Additional description: Erectile dysfunction		
	1 / 278 (0.36%) 7	0 / 279 (0.00%) 0	
Prostatitis subjects affected / exposed occurrences (all)	Additional description: Prostatitis		
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Testicular pain subjects affected / exposed occurrences (all)	Additional description: Testicular pain		
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Vaginal discharge subjects affected / exposed occurrences (all)	Additional description: Vaginal discharge		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Vulvovaginal dryness subjects affected / exposed occurrences (all)	Additional description: Vulvovaginal dryness		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Respiratory, thoracic and mediastinal disorders			
Allergic bronchitis subjects affected / exposed occurrences (all)	Additional description: Allergic bronchitis		
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Bronchitis chronic subjects affected / exposed occurrences (all)	Additional description: Bronchitis chronic		
	2 / 278 (0.72%) 2	1 / 279 (0.36%) 1	
Bronchospasm subjects affected / exposed occurrences (all)	Additional description: Bronchospasm		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	Additional description: Chronic obstructive pulmonary disease		
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 2	

Chylothorax	Additional description: Chylothorax	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences (all)	1	0
Cough	Additional description: Cough	
subjects affected / exposed	10 / 278 (3.60%)	18 / 279 (6.45%)
occurrences (all)	11	25
Cough decreased	Additional description: Cough decreased	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Dyspnoea	Additional description: Dyspnoea	
subjects affected / exposed	3 / 278 (1.08%)	4 / 279 (1.43%)
occurrences (all)	11	7
Dyspnoea exertional	Additional description: Dyspnoea exertional	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences (all)	1	0
Epistaxis	Additional description: Epistaxis	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences (all)	2	0
Oropharyngeal pain	Additional description: Oropharyngeal pain	
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)
occurrences (all)	2	1
Pleural effusion	Additional description: Pleural effusion	
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)
occurrences (all)	0	2
Productive cough	Additional description: Productive cough	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Rhinitis allergic	Additional description: Rhinitis allergic	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Rhinitis atrophic	Additional description: Rhinitis atrophic	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences (all)	1	0
Rhinorrhoea	Additional description: Rhinorrhoea	
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)
occurrences (all)	0	3

Psychiatric disorders			
Depression	Additional description: Depression		
subjects affected / exposed	4 / 278 (1.44%)	2 / 279 (0.72%)	
occurrences (all)	6	2	
Insomnia	Additional description: Insomnia		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences (all)	4	2	
Schizophrenia	Additional description: Schizophrenia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Investigations			
Alanine aminotransferase	Additional description: Alanine aminotransferase		
subjects affected / exposed	0 / 278 (0.00%)	3 / 279 (1.08%)	
occurrences (all)	0	5	
Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased		
subjects affected / exposed	0 / 278 (0.00%)	3 / 279 (1.08%)	
occurrences (all)	0	4	
Aspartate aminotransferase	Additional description: Aspartate aminotransferase		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	4	
Aspartate aminotransferase increased	Additional description: Aspartate aminotransferase increased		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences (all)	0	2	
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences (all)	1	1	
Blood creatinine	Additional description: Blood creatinine		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Blood bilirubin	Additional description: Blood bilirubin		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Blood alkaline phosphatase increased	Additional description: Blood alkaline phosphatase increased		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Blood lactate dehydrogenase increased	Additional description: Blood lactate dehydrogenase increased		

subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Body temperature increased subjects affected / exposed occurrences (all)	Additional description: Body temperature increased		
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Blood potassium decreased subjects affected / exposed occurrences (all)	Additional description: Blood potassium decreased		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2	
C-reactive protein increased subjects affected / exposed occurrences (all)	Additional description: C-reactive protein increased		
	2 / 278 (0.72%) 2	0 / 279 (0.00%) 0	
CD4 lymphocytes subjects affected / exposed occurrences (all)	Additional description: CD4 lymphocytes		
	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0	
CD4 lymphocytes decreased subjects affected / exposed occurrences (all)	Additional description: CD4 lymphocytes decreased		
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 9	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	Additional description: Gamma-glutamyltransferase increased		
	0 / 278 (0.00%) 0	3 / 279 (1.08%) 4	
Gamma-glutamyltransferase subjects affected / exposed occurrences (all)	Additional description: Gamma-glutamyltransferase		
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 11	
Haemoglobin subjects affected / exposed occurrences (all)	Additional description: Haemoglobin		
	9 / 278 (3.24%) 17	10 / 279 (3.58%) 35	
Granulocytes abnormal subjects affected / exposed occurrences (all)	Additional description: Granulocytes abnormal		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 5	
Haemoglobin decreased subjects affected / exposed occurrences (all)	Additional description: Haemoglobin decreased		
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 3	
Hepatitis B antibody positive subjects affected / exposed occurrences (all)	Additional description: Hepatitis B antibody positive		
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	

Hepatic enzyme increased subjects affected / exposed occurrences (all)	Additional description: Hepatic enzyme increased	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 2
Immunoglobulins decreased subjects affected / exposed occurrences (all)	Additional description: Immunoglobulins decreased	
	1 / 278 (0.36%) 3	1 / 279 (0.36%) 1
Intraocular pressure increased subjects affected / exposed occurrences (all)	Additional description: Intraocular pressure increased	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Lipase subjects affected / exposed occurrences (all)	Additional description: Lipase	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Neutrophil count subjects affected / exposed occurrences (all)	Additional description: Neutrophil count	
	20 / 278 (7.19%) 41	33 / 279 (11.83%) 89
Neutrophil count decreased subjects affected / exposed occurrences (all)	Additional description: Neutrophil count decreased	
	1 / 278 (0.36%) 2	3 / 279 (1.08%) 3
Platelet count subjects affected / exposed occurrences (all)	Additional description: Platelet count	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Platelet count decreased subjects affected / exposed occurrences (all)	Additional description: Platelet count decreased	
	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0
Prothrombin time shortened subjects affected / exposed occurrences (all)	Additional description: Prothrombin time shortened	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Transaminases increased subjects affected / exposed occurrences (all)	Additional description: Transaminases increased	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
White blood cell count subjects affected / exposed occurrences (all)	Additional description: White blood cell count	
	15 / 278 (5.40%) 38	26 / 279 (9.32%) 92
Weight decreased subjects affected / exposed occurrences (all)	Additional description: Weight decreased	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0

Injury, poisoning and procedural complications			
Arterial injury	Additional description: Arterial injury		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	8	
Foot fracture	Additional description: Foot fracture		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed	2 / 278 (0.72%)	3 / 279 (1.08%)	
occurrences (all)	2	3	
Meniscus injury	Additional description: Meniscus injury		
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)	
occurrences (all)	2	1	
Postoperative fever	Additional description: Postoperative fever		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Skull fracture	Additional description: Skull fracture		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Wound	Additional description: Wound		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences (all)	1	1	
Cardiac disorders			
Angina pectoris	Additional description: Angina pectoris		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Arrhythmia	Additional description: Arrhythmia		
subjects affected / exposed	3 / 278 (1.08%)	1 / 279 (0.36%)	
occurrences (all)	3	1	
Atrial fibrillation	Additional description: Atrial fibrillation		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)	
occurrences (all)	0	1	
Myocardial ischaemia	Additional description: Myocardial ischaemia		

subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0	
Tachyarrhythmia	Additional description: Tachyarrhythmia		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Nervous system disorders			
Carotid artery stenosis	Additional description: Carotid artery stenosis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Carpal tunnel syndrome	Additional description: Carpal tunnel syndrome		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 4	
Cervicogenic headache	Additional description: Cervicogenic headache		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Depressed level of consciousness	Additional description: Depressed level of consciousness		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Dizziness	Additional description: Dizziness		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2	
Dystonia	Additional description: Dystonia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Headache	Additional description: Headache		
subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 3	0 / 279 (0.00%) 0	
Hypoaesthesia	Additional description: Hypoaesthesia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Monoparesis	Additional description: Monoparesis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	

Migraine with aura subjects affected / exposed occurrences (all)	Additional description: Migraine with aura	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Memory impairment subjects affected / exposed occurrences (all)	Additional description: Memory impairment	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	Additional description: Neuralgia	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Paraesthesia subjects affected / exposed occurrences (all)	Additional description: Paraesthesia	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Paresis cranial nerve subjects affected / exposed occurrences (all)	Additional description: Paresis cranial nerve	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Parkinson's disease subjects affected / exposed occurrences (all)	Additional description: Parkinson's disease	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	Additional description: Peripheral sensory neuropathy	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Polyneuropathy subjects affected / exposed occurrences (all)	Additional description: Polyneuropathy	
	3 / 278 (1.08%) 10	2 / 279 (0.72%) 2
Post herpetic neuralgia subjects affected / exposed occurrences (all)	Additional description: Post herpetic neuralgia	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 5
Restless legs syndrome subjects affected / exposed occurrences (all)	Additional description: Restless legs syndrome	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	Additional description: Syncope	
	3 / 278 (1.08%) 3	0 / 279 (0.00%) 0
Transient ischaemic attack subjects affected / exposed occurrences (all)	Additional description: Transient ischaemic attack	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1

Blood and lymphatic system disorders			
Anaemia vitamin B12 deficiency	Additional description: Anaemia vitamin B12 deficiency		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Anaemia folate deficiency	Additional description: Anaemia folate deficiency		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Anaemia	Additional description: Anaemia		
subjects affected / exposed	18 / 278 (6.47%)	26 / 279 (9.32%)	
occurrences (all)	30	39	
Autoimmune haemolytic anaemia	Additional description: Autoimmune haemolytic anaemia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	4 / 278 (1.44%)	4 / 279 (1.43%)	
occurrences (all)	6	4	
Granulocytopenia	Additional description: Granulocytopenia		
subjects affected / exposed	3 / 278 (1.08%)	3 / 279 (1.08%)	
occurrences (all)	4	3	
Haemolytic anaemia	Additional description: Haemolytic anaemia		
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)	
occurrences (all)	1	0	
Haemolysis	Additional description: Haemolysis		
subjects affected / exposed	1 / 278 (0.36%)	1 / 279 (0.36%)	
occurrences (all)	2	1	
Leukopenia	Additional description: Leukopenia		
subjects affected / exposed	127 / 278 (45.68%)	208 / 279 (74.55%)	
occurrences (all)	321	818	
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	153 / 278 (55.04%)	216 / 279 (77.42%)	
occurrences (all)	369	802	
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	0 / 278 (0.00%)	2 / 279 (0.72%)	
occurrences (all)	0	3	
Platelet disorder	Additional description: Platelet disorder		

subjects affected / exposed occurrences (all)	5 / 278 (1.80%) 6	8 / 279 (2.87%) 22	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed occurrences (all)	45 / 278 (16.19%) 86	61 / 279 (21.86%) 138	
Ear and labyrinth disorders			
Deafness	Additional description: Deafness		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Hearing impaired	Additional description: Hearing impaired		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Vestibular disorder	Additional description: Vestibular disorder		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2	
Vertigo	Additional description: Vertigo		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Eye disorders			
Age-related macular degeneration	Additional description: Age-related macular degeneration		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Glaucoma	Additional description: Glaucoma		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0	
Lacrimation increased	Additional description: Lacrimation increased		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Visual impairment	Additional description: Visual impairment		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 3	0 / 279 (0.00%) 0	
Gastrointestinal disorders			

Abdominal distension subjects affected / exposed occurrences (all)	Additional description: Abdominal distension	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	Additional description: Abdominal pain upper	
	2 / 278 (0.72%) 2	0 / 279 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	Additional description: Abdominal pain	
	1 / 278 (0.36%) 1	3 / 279 (1.08%) 3
Anal fissure subjects affected / exposed occurrences (all)	Additional description: Anal fissure	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Anal prolapse subjects affected / exposed occurrences (all)	Additional description: Anal prolapse	
	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0
Anal ulcer subjects affected / exposed occurrences (all)	Additional description: Anal ulcer	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Aphthous stomatitis subjects affected / exposed occurrences (all)	Additional description: Aphthous stomatitis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Chronic gastritis subjects affected / exposed occurrences (all)	Additional description: Chronic gastritis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	Additional description: Colitis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Constipation subjects affected / exposed occurrences (all)	Additional description: Constipation	
	1 / 278 (0.36%) 1	2 / 279 (0.72%) 2
Diarrhoea subjects affected / exposed occurrences (all)	Additional description: Diarrhoea	
	2 / 278 (0.72%) 2	4 / 279 (1.43%) 6
Dyspepsia subjects affected / exposed occurrences (all)	Additional description: Dyspepsia	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1

Enteritis subjects affected / exposed occurrences (all)	Additional description: Enteritis	
	1 / 278 (0.36%) 1	2 / 279 (0.72%) 2
Enterocolitis subjects affected / exposed occurrences (all)	Additional description: Enterocolitis	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Gastric ulcer subjects affected / exposed occurrences (all)	Additional description: Gastric ulcer	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Gastritis subjects affected / exposed occurrences (all)	Additional description: Gastritis	
	3 / 278 (1.08%) 5	0 / 279 (0.00%) 0
Gastroesophageal reflux disease subjects affected / exposed occurrences (all)	Additional description: Gastroesophageal reflux disease	
	3 / 278 (1.08%) 4	0 / 279 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	Additional description: Haemorrhoids	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Ileus subjects affected / exposed occurrences (all)	Additional description: Ileus	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Inguinal hernia subjects affected / exposed occurrences (all)	Additional description: Inguinal hernia	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Nausea subjects affected / exposed occurrences (all)	Additional description: Nausea	
	7 / 278 (2.52%) 7	5 / 279 (1.79%) 8
Oral mucosal discolouration subjects affected / exposed occurrences (all)	Additional description: Oral mucosal discolouration	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Periodontal inflammation subjects affected / exposed occurrences (all)	Additional description: Periodontal inflammation	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Stomatitis subjects affected / exposed occurrences (all)	Additional description: Stomatitis	
	0 / 278 (0.00%) 0	4 / 279 (1.43%) 4

Toothache subjects affected / exposed occurrences (all)	Additional description: Toothache	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Tooth loss subjects affected / exposed occurrences (all)	Additional description: Tooth loss	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Vomiting subjects affected / exposed occurrences (all)	Additional description: Vomiting	
	5 / 278 (1.80%) 5	4 / 279 (1.43%) 6
Hepatobiliary disorders	Additional description: Cholelithiasis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
	Additional description: Hepatitis alcoholic	
Hepatitis alcoholic subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2
	Additional description: Hyperbilirubinaemia	
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 2
	Additional description: Acne	
Skin and subcutaneous tissue disorders	Additional description: Acne	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Actinic keratosis subjects affected / exposed occurrences (all)	Additional description: Actinic keratosis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Blister subjects affected / exposed occurrences (all)	Additional description: Blister	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Dermatitis allergic subjects affected / exposed occurrences (all)	Additional description: Dermatitis allergic	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Dermatitis psoriasiform subjects affected / exposed occurrences (all)	Additional description: Dermatitis psoriasiform	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Dry skin	Additional description: Dry skin	

subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Eczema	Additional description: Eczema		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 3	2 / 279 (0.72%) 2	
Erythema	Additional description: Erythema		
subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 4	5 / 279 (1.79%) 10	
Erythema nodosum	Additional description: Erythema nodosum		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Erythema multiforme	Additional description: Erythema multiforme		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Hyperhidrosis	Additional description: Hyperhidrosis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	4 / 279 (1.43%) 6	
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 4	0 / 279 (0.00%) 0	
Neurodermatitis	Additional description: Neurodermatitis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 11	
Petechiae	Additional description: Petechiae		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Photosensitivity reaction	Additional description: Photosensitivity reaction		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Pruritus	Additional description: Pruritus		
subjects affected / exposed occurrences (all)	11 / 278 (3.96%) 16	8 / 279 (2.87%) 12	
Psoriasis	Additional description: Psoriasis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Rash	Additional description: Rash		

subjects affected / exposed occurrences (all)	16 / 278 (5.76%) 30	16 / 279 (5.73%) 18	
Rash generalised	Additional description: Rash generalised		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 6	
Rash pruritic	Additional description: Rash pruritic		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Rash papular	Additional description: Rash papular		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Skin exfoliation	Additional description: Skin exfoliation		
subjects affected / exposed occurrences (all)	5 / 278 (1.80%) 7	0 / 279 (0.00%) 0	
Skin lesion	Additional description: Skin lesion		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	0 / 279 (0.00%) 0	
Skin texture abnormal	Additional description: Skin texture abnormal		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Skin ulcer	Additional description: Skin ulcer		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 4	
Urticaria	Additional description: Urticaria		
subjects affected / exposed occurrences (all)	5 / 278 (1.80%) 7	1 / 279 (0.36%) 1	
Renal and urinary disorders			
Cystitis noninfective	Additional description: Cystitis noninfective		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Dysuria	Additional description: Dysuria		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	

Pollakiuria subjects affected / exposed occurrences (all)	Additional description: Pollakiuria	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Renal colic subjects affected / exposed occurrences (all)	Additional description: Renal colic	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Renal failure subjects affected / exposed occurrences (all)	Additional description: Renal failure	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Stress urinary incontinence subjects affected / exposed occurrences (all)	Additional description: Stress urinary incontinence	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Endocrine disorders Autoimmune thyroiditis subjects affected / exposed occurrences (all)	Additional description: Autoimmune thyroiditis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
	Additional description: Hyperthyroidism	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	Additional description: Arthralgia	
	3 / 278 (1.08%) 6	4 / 279 (1.43%) 9
	Additional description: Arthritis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
	Additional description: Arthrofibrosis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
	Additional description: Back pain	
	3 / 278 (1.08%) 6	4 / 279 (1.43%) 6
	Additional description: Intervertebral disc protrusion	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Musculoskeletal pain	Additional description: Musculoskeletal pain	

subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 5	0 / 279 (0.00%) 0	
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Neck pain	Additional description: Neck pain		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed occurrences (all)	3 / 278 (1.08%) 5	2 / 279 (0.72%) 6	
Osteopenia	Additional description: Osteopenia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2	
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 3	0 / 279 (0.00%) 0	
Polyarthritis	Additional description: Polyarthritis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 2	0 / 279 (0.00%) 0	
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 3	0 / 279 (0.00%) 0	
Rheumatoid arthritis	Additional description: Rheumatoid arthritis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 6	0 / 279 (0.00%) 0	
Scoliosis	Additional description: Scoliosis		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Rotator cuff syndrome	Additional description: Rotator cuff syndrome		

subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2	
Seronegative arthritis	Additional description: Seronegative arthritis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 3	0 / 279 (0.00%) 0	
Spinal osteoarthritis	Additional description: Spinal osteoarthritis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Infections and infestations			
Abscess	Additional description: Abscess		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Abscess jaw	Additional description: Abscess jaw		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Acute tonsillitis	Additional description: Acute tonsillitis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Aspergillus infection	Additional description: Aspergillus infection		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Bacteraemia	Additional description: Bacteraemia		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0	
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed occurrences (all)	31 / 278 (11.15%) 44	30 / 279 (10.75%) 47	
Bronchopneumonia	Additional description: Bronchopneumonia		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	3 / 279 (1.08%) 5	
Campylobacter gastroenteritis	Additional description: Campylobacter gastroenteritis		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1	
Candida infection	Additional description: Candida infection		
subjects affected / exposed occurrences (all)	2 / 278 (0.72%) 2	1 / 279 (0.36%) 2	

Chronic sinusitis subjects affected / exposed occurrences (all)	Additional description: Chronic sinusitis	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Conjunctivitis subjects affected / exposed occurrences (all)	Additional description: Conjunctivitis	
	3 / 278 (1.08%) 3	2 / 279 (0.72%) 2
Cytomegalovirus infection subjects affected / exposed occurrences (all)	Additional description: Cytomegalovirus infection	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Cystitis subjects affected / exposed occurrences (all)	Additional description: Cystitis	
	2 / 278 (0.72%) 2	3 / 279 (1.08%) 5
Diverticulitis subjects affected / exposed occurrences (all)	Additional description: Diverticulitis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Dysentery subjects affected / exposed occurrences (all)	Additional description: Dysentery	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	Additional description: Ear infection	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Erysipelas subjects affected / exposed occurrences (all)	Additional description: Erysipelas	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Erythema migrans subjects affected / exposed occurrences (all)	Additional description: Erythema migrans	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Febrile infection subjects affected / exposed occurrences (all)	Additional description: Febrile infection	
	7 / 278 (2.52%) 7	7 / 279 (2.51%) 7
Fungal infection subjects affected / exposed occurrences (all)	Additional description: Fungal infection	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Fungal skin infection subjects affected / exposed occurrences (all)	Additional description: Fungal skin infection	
	1 / 278 (0.36%) 1	2 / 279 (0.72%) 2

Furuncle subjects affected / exposed occurrences (all)	Additional description: Furuncle	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis	
	2 / 278 (0.72%) 2	3 / 279 (1.08%) 3
Gastrointestinal infection subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal infection	
	3 / 278 (1.08%) 3	3 / 279 (1.08%) 3
Gastroenteritis norovirus subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis norovirus	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Gingivitis subjects affected / exposed occurrences (all)	Additional description: Gingivitis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Genital infection fungal subjects affected / exposed occurrences (all)	Additional description: Genital infection fungal	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
H1N1 influenza subjects affected / exposed occurrences (all)	Additional description: H1N1 influenza	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Hepatitis E subjects affected / exposed occurrences (all)	Additional description: Hepatitis E	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	Additional description: Herpes zoster	
	16 / 278 (5.76%) 19	31 / 279 (11.11%) 34
Herpes virus infection subjects affected / exposed occurrences (all)	Additional description: Herpes virus infection	
	5 / 278 (1.80%) 6	9 / 279 (3.23%) 12
Herpes simplex subjects affected / exposed occurrences (all)	Additional description: Herpes simplex	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Infection susceptibility increased subjects affected / exposed occurrences (all)	Additional description: Infection susceptibility increased	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1

Infection	Additional description: Infection	
subjects affected / exposed	18 / 278 (6.47%)	12 / 279 (4.30%)
occurrences (all)	20	12
Infected varicose vein	Additional description: Infected varicose vein	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Infected bites	Additional description: Infected bites	
subjects affected / exposed	1 / 278 (0.36%)	0 / 279 (0.00%)
occurrences (all)	1	0
Influenza	Additional description: Influenza	
subjects affected / exposed	10 / 278 (3.60%)	5 / 279 (1.79%)
occurrences (all)	11	5
Laryngitis	Additional description: Laryngitis	
subjects affected / exposed	2 / 278 (0.72%)	1 / 279 (0.36%)
occurrences (all)	2	1
Laryngitis bacterial	Additional description: Laryngitis bacterial	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Localised infection	Additional description: Localised infection	
subjects affected / exposed	4 / 278 (1.44%)	2 / 279 (0.72%)
occurrences (all)	4	2
Lung infection	Additional description: Lung infection	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Lyme disease	Additional description: Lyme disease	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Mastitis	Additional description: Mastitis	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	1
Nasopharyngitis	Additional description: Nasopharyngitis	
subjects affected / exposed	52 / 278 (18.71%)	52 / 279 (18.64%)
occurrences (all)	67	72
Muscle abscess	Additional description: Muscle abscess	
subjects affected / exposed	0 / 278 (0.00%)	1 / 279 (0.36%)
occurrences (all)	0	2

Oesophageal candidiasis subjects affected / exposed occurrences (all)	Additional description: Oesophageal candidiasis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Ophthalmic herpes zoster subjects affected / exposed occurrences (all)	Additional description: Ophthalmic herpes zoster	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Oral fungal infection subjects affected / exposed occurrences (all)	Additional description: Oral fungal infection	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Oral infection subjects affected / exposed occurrences (all)	Additional description: Oral infection	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Oral herpes subjects affected / exposed occurrences (all)	Additional description: Oral herpes	
	17 / 278 (6.12%) 23	17 / 279 (6.09%) 19
Otitis media subjects affected / exposed occurrences (all)	Additional description: Otitis media	
	2 / 278 (0.72%) 2	3 / 279 (1.08%) 3
Pharyngitis subjects affected / exposed occurrences (all)	Additional description: Pharyngitis	
	9 / 278 (3.24%) 9	5 / 279 (1.79%) 5
Pharyngeal chlamydia infection subjects affected / exposed occurrences (all)	Additional description: Pharyngeal chlamydia infection	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	Additional description: Pneumocystis jirovecii pneumonia	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	Additional description: Pneumonia	
	13 / 278 (4.68%) 17	16 / 279 (5.73%) 16
Postoperative wound infection subjects affected / exposed occurrences (all)	Additional description: Postoperative wound infection	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Pulmonary mycosis subjects affected / exposed occurrences (all)	Additional description: Pulmonary mycosis	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1

Pyelonephritis subjects affected / exposed occurrences (all)	Additional description: Pyelonephritis	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Respiratory tract infection	
	6 / 278 (2.16%) 7	15 / 279 (5.38%) 21
Rhinitis subjects affected / exposed occurrences (all)	Additional description: Rhinitis	
	5 / 278 (1.80%) 5	6 / 279 (2.15%) 7
Sinobronchitis subjects affected / exposed occurrences (all)	Additional description: Sinobronchitis	
	1 / 278 (0.36%) 1	2 / 279 (0.72%) 3
Sinusitis subjects affected / exposed occurrences (all)	Additional description: Sinusitis	
	10 / 278 (3.60%) 13	19 / 279 (6.81%) 28
Skin bacterial infection subjects affected / exposed occurrences (all)	Additional description: Skin bacterial infection	
	1 / 278 (0.36%) 1	2 / 279 (0.72%) 2
Skin infection subjects affected / exposed occurrences (all)	Additional description: Skin infection	
	1 / 278 (0.36%) 1	3 / 279 (1.08%) 3
Staphylococcal infection subjects affected / exposed occurrences (all)	Additional description: Staphylococcal infection	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Tooth abscess subjects affected / exposed occurrences (all)	Additional description: Tooth abscess	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2
Tooth infection subjects affected / exposed occurrences (all)	Additional description: Tooth infection	
	2 / 278 (0.72%) 2	3 / 279 (1.08%) 3
Tonsillitis subjects affected / exposed occurrences (all)	Additional description: Tonsillitis	
	3 / 278 (1.08%) 3	3 / 279 (1.08%) 3
Tracheobronchitis subjects affected / exposed occurrences (all)	Additional description: Tracheobronchitis	
	0 / 278 (0.00%) 0	2 / 279 (0.72%) 2

Vaginal infection subjects affected / exposed occurrences (all)	Additional description: Vaginal infection	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection	
	16 / 278 (5.76%) 18	12 / 279 (4.30%) 23
Upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Upper respiratory tract infection	
	25 / 278 (8.99%) 32	50 / 279 (17.92%) 75
Vaccination site infection subjects affected / exposed occurrences (all)	Additional description: Vaccination site infection	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Varicella subjects affected / exposed occurrences (all)	Additional description: Varicella	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Viral infection subjects affected / exposed occurrences (all)	Additional description: Viral infection	
	4 / 278 (1.44%) 4	5 / 279 (1.79%) 5
Wound infection subjects affected / exposed occurrences (all)	Additional description: Wound infection	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Metabolism and nutrition disorders		
Decreased appetite subjects affected / exposed occurrences (all)	Additional description: Decreased appetite	
	1 / 278 (0.36%) 1	1 / 279 (0.36%) 1
Folate deficiency subjects affected / exposed occurrences (all)	Additional description: Folate deficiency	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 6
Gout subjects affected / exposed occurrences (all)	Additional description: Gout	
	1 / 278 (0.36%) 1	0 / 279 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	Additional description: Hypercholesterolaemia	
	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1
Hyperglycaemia	Additional description: Hyperglycaemia	

subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	2 / 279 (0.72%) 3	
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 1	
Iron overload	Additional description: Iron overload		
subjects affected / exposed occurrences (all)	0 / 278 (0.00%) 0	1 / 279 (0.36%) 2	
Vitamin B12 deficiency	Additional description: Vitamin B12 deficiency		
subjects affected / exposed occurrences (all)	1 / 278 (0.36%) 1	1 / 279 (0.36%) 6	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 June 2010	Global Amendment with German Protocol version 3.1 and date 25.06.2010 was submitted separately in each Country.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27216274>